These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 27174193)

  • 1. A non-commercial approach for the generation of transgenic Leishmania tarentolae and its application in antileishmanial drug discovery.
    Pineda T; Valencia Y; Flórez MF; Pulido SA; Vélez ID; Robledo SM
    Parasitology; 2016 Aug; 143(9):1133-42. PubMed ID: 27174193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement of the green fluorescent protein reporter system in Leishmania spp. for the in vitro and in vivo screening of antileishmanial drugs.
    Pulido SA; Muñoz DL; Restrepo AM; Mesa CV; Alzate JF; Vélez ID; Robledo SM
    Acta Trop; 2012 Apr; 122(1):36-45. PubMed ID: 22155571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leishmania tarentolae: utility as an in vitro model for screening of antileishmanial agents.
    Taylor VM; Muñoz DL; Cedeño DL; Vélez ID; Jones MA; Robledo SM
    Exp Parasitol; 2010 Dec; 126(4):471-5. PubMed ID: 20685203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies in vitro on infectivity and sensitivity to antileishmanial drugs in New World Leishmania species transfected with the green fluorescent protein [pIR3(-)-eGFP].
    Palacios G; Parodi A; Upegui YA; Montoya A; Pulido S; Vélez ID; Robledo SM
    Parasitology; 2017 Nov; 144(13):1718-1725. PubMed ID: 28831945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and validation of four Leishmania species constitutively expressing GFP protein. A model for drug discovery and disease pathogenesis studies.
    Patel AP; Deacon A; Getti G
    Parasitology; 2014 Apr; 141(4):501-10. PubMed ID: 24252638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluorescent Leishmania species: development of stable GFP expression and its application for in vitro and in vivo studies.
    Bolhassani A; Taheri T; Taslimi Y; Zamanilui S; Zahedifard F; Seyed N; Torkashvand F; Vaziri B; Rafati S
    Exp Parasitol; 2011 Mar; 127(3):637-45. PubMed ID: 21187086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of Leishmania donovani stably expressing DsRed for flow cytometry-based drug screening using chalcone thiazolyl-hydrazone as a new antileishmanial target.
    Jaiswal AK; Rao KB; Kushwaha P; Rawat K; Modukuri RK; Khare P; Joshi S; Mishra S; Rai A; Sashidhara KV; Dube A
    Int J Antimicrob Agents; 2016 Dec; 48(6):695-702. PubMed ID: 27876275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An alternative in vitro drug screening test using Leishmania amazonensis transfected with red fluorescent protein.
    Rocha MN; Corrêa CM; Melo MN; Beverley SM; Martins-Filho OA; Madureira AP; Soares RP
    Diagn Microbiol Infect Dis; 2013 Mar; 75(3):282-91. PubMed ID: 23312610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An ex vivo multiparametric flow cytometry assay using human whole blood to simultaneously measure cytotoxicity and leishmanicidal activities.
    Ribeiro JM; Bandeira CC; de Faria BG; Alves MLR; Vieira FO; Giunchetti RC; Uzonna JE; Teixeira-Carvalho A; Peruhype-Magalhães V; Souza-Fagundes EM
    Exp Parasitol; 2020 Sep; 216():107940. PubMed ID: 32562606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-throughput screening platform for natural product-based drug discovery against 3 neglected tropical diseases: human African trypanosomiasis, leishmaniasis, and Chagas disease.
    Annang F; Pérez-Moreno G; García-Hernández R; Cordon-Obras C; Martín J; Tormo JR; Rodríguez L; de Pedro N; Gómez-Pérez V; Valente M; Reyes F; Genilloud O; Vicente F; Castanys S; Ruiz-Pérez LM; Navarro M; Gamarro F; González-Pacanowska D
    J Biomol Screen; 2015 Jan; 20(1):82-91. PubMed ID: 25332350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Vitro Infectivity Assessment by Drug Susceptibility Comparison of Recombinant Leishmania major Expressing Enhanced Green Fluorescent Protein or EGFP-Luciferase Fused Genes with Wild-Type Parasite.
    Sadeghi S; Seyed N; Etemadzadeh MH; Abediankenari S; Rafati S; Taheri T
    Korean J Parasitol; 2015 Aug; 53(4):385-94. PubMed ID: 26323836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transgenic Leishmania donovani clinical isolates expressing green fluorescent protein constitutively for rapid and reliable ex vivo drug screening.
    Singh N; Gupta R; Jaiswal AK; Sundar S; Dube A
    J Antimicrob Chemother; 2009 Aug; 64(2):370-4. PubMed ID: 19525291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repurposing as a strategy for the discovery of new anti-leishmanials: the-state-of-the-art.
    Charlton RL; Rossi-Bergmann B; Denny PW; Steel PG
    Parasitology; 2018 Feb; 145(2):219-236. PubMed ID: 28805165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 4-Arylamino-6-nitroquinazolines: Synthesis and their activities against neglected disease leishmaniasis.
    Saad SM; Ghouri N; Perveen S; Khan KM; Choudhary MI
    Eur J Med Chem; 2016 Jan; 108():13-20. PubMed ID: 26619389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure/antileishmanial activity relationship study of naphthoquinones and dependency of the mode of action on the substitution patterns.
    Ali A; Assimopoulou AN; Papageorgiou VP; Kolodziej H
    Planta Med; 2011 Dec; 77(18):2003-12. PubMed ID: 21800278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The enemy within: Targeting host-parasite interaction for antileishmanial drug discovery.
    Lamotte S; Späth GF; Rachidi N; Prina E
    PLoS Negl Trop Dis; 2017 Jun; 11(6):e0005480. PubMed ID: 28594938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of stable L. major(+EGFP-LUC) and simultaneous comparison between EGFP and luciferase sensitivity.
    Taheri T; Saberi Nik H; Seyed N; Doustdari F; Etemadzadeh MH; Torkashvand F; Rafati S
    Exp Parasitol; 2015 Mar; 150():44-55. PubMed ID: 25637784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-throughput prioritization of target proteins for development of new antileishmanial compounds.
    Azevedo LG; Sosa E; de Queiroz ATL; Barral A; Wheeler RJ; Nicolás MF; Farias LP; Do Porto DF; Ramos PIP
    Int J Parasitol Drugs Drug Resist; 2024 Aug; 25():100538. PubMed ID: 38669848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Auranofin is an apoptosis-simulating agent with in vitro and in vivo anti-leishmanial activity.
    Sharlow ER; Leimgruber S; Murray S; Lira A; Sciotti RJ; Hickman M; Hudson T; Leed S; Caridha D; Barrios AM; Close D; Grögl M; Lazo JS
    ACS Chem Biol; 2014 Mar; 9(3):663-72. PubMed ID: 24328400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances and perspectives in Leishmania cell based drug-screening procedures.
    Sereno D; Cordeiro da Silva A; Mathieu-Daude F; Ouaissi A
    Parasitol Int; 2007 Mar; 56(1):3-7. PubMed ID: 17079188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.